Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) has been given a consensus rating of “Buy” by the six ratings firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $26.33.

A number of equities research analysts recently commented on the company. Cantor Fitzgerald set a $29.00 price target on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 16th. Chardan Capital restated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research report on Monday, November 6th. B. Riley initiated coverage on Spring Bank Pharmaceuticals in a report on Monday, November 6th. They set a “buy” rating and a $30.00 price objective on the stock. Finally, ValuEngine downgraded Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st.

Shares of Spring Bank Pharmaceuticals (NASDAQ SBPH) opened at $12.71 on Tuesday. The company has a market capitalization of $164.61, a P/E ratio of -4.62 and a beta of 1.99. Spring Bank Pharmaceuticals has a 12-month low of $6.31 and a 12-month high of $18.93.

A number of large investors have recently bought and sold shares of SBPH. AXA acquired a new position in Spring Bank Pharmaceuticals during the 2nd quarter worth $2,894,000. Sphera Funds Management LTD. acquired a new position in Spring Bank Pharmaceuticals during the 2nd quarter worth $2,370,000. Sectoral Asset Management Inc acquired a new position in Spring Bank Pharmaceuticals during the 2nd quarter worth $1,523,000. C WorldWide Group Holding A S lifted its stake in shares of Spring Bank Pharmaceuticals by 342.6% in the 3rd quarter. C WorldWide Group Holding A S now owns 111,200 shares of the company’s stock valued at $1,873,000 after purchasing an additional 86,077 shares during the period. Finally, Morse Asset Management Inc lifted its stake in shares of Spring Bank Pharmaceuticals by 94.7% in the 3rd quarter. Morse Asset Management Inc now owns 124,000 shares of the company’s stock valued at $2,004,000 after purchasing an additional 60,300 shares during the period. 29.70% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Spring Bank Pharmaceuticals Inc (SBPH) Receives Average Recommendation of “Buy” from Analysts” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://theolympiareport.com/2017/12/26/spring-bank-pharmaceuticals-inc-sbph-receives-average-recommendation-of-buy-from-analysts.html.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.

Analyst Recommendations for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.